Switching from semaglutide to tirzepatide This is the most common protocol transition in 2026
April 15, 2008 FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight FDA.gov March 8, 2024 HPMS Memos for WK 4 March 18-22 CMS.gov
Women experiencing menopause, individuals with thyroid disorders, or those with insulin resistance may see different results compared to metabolically healthy individuals
"The majority of our members are on a medication of some sort, and it's because they typically struggle with obesity and they've been trying to solve it through a lens of just eat less, exercise more," Found's CEO, Sarah Jones Simmer, told Insider in an interview
[DOI] [PMC free article] [PubMed] [Google Scholar] 70.Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, et al